Workflow
Daikyo Crystal Zenith® and Administration Systems
icon
Search documents
West Pharmaceutical(WST) - 2025 Q2 - Earnings Call Presentation
2025-07-24 12:00
Financial Performance - Second-quarter net sales reached $766.5 million, a 9.2% increase[1] - Organic net sales grew by 6.8%[19] - Reported-diluted EPS was $1.82, compared to $1.51 in the same period last year[19] - Adjusted-diluted EPS was $1.84, compared to $1.52 last year[1] Segment Performance - HVP Components revenues increased by 11.3%[22] - GLP-1 elastomer products accounted for 8% of total company revenues[22] - HVP Delivery Devices revenues increased by 30.0% and represented 13% of total company sales[25] - Contract Manufacturing revenues increased 0.5% on an organic basis[28] Guidance - Revenue guidance for fiscal year 2025 is increased to $3.040 - $3.060 billion[29, 40] - Adjusted EPS guidance for fiscal year 2025 is increased to $6.65 to $6.85[29, 40]